Andere Sprachen Imugene Limited

Aktien

891460

AU000000IMU9

IMU

Verzögert Australian S.E. Andere Börsenplätze 03:05:18 30.04.2024			% 5 Tage	% 1. Jan.
0,0845 ^AUD	+3,05 %		-0,59 %	-23,18 %

15.04.	Imugene Limited gibt bekannt, dass die Rekrutierung für die Erweiterungsstudie bei Patienten mit Gallengangskrebs (Cholangiokarzinom) eröffnet wurde	CI
04.04.	Imugene sichert das Patent für die onkolytische Virotherapie CF33 in China	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Imugene partners with Kincell Bio; selling cell therapy manufacturing facility for $6 million	16.04.
Imugene Signs Deal to Sell Manufacturing Facility For $6 Million	16.04.
Kincell Bio, LLC signed an asset purchase agreement to acquire North Carolina manufacturing facility from Imugene Limited for $6 million.	16.04.
Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort	15.04.
Imugene Limited Announce Enrolment Opened for Its Expansion Study in Bile Tract Cancer (Cholangiocarcinoma) Patients	15.04.
Imugene opens enrolment for Bile Tract Cancer expansion study	15.04.
Imugene Commences Enrolment for Cholangiocarcinoma Expansion Study	15.04.
Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024	09.04.
Imugene Secures Patent for Oncolytic Virotherapy CF33 in China	04.04.
Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12%	20.03.
Imugene progresses onCARlytics solid tumour trial to combination arm	11.03.
Phase 1 onCARlytics solid tumour trial advances to combination arm treatment	11.03.
Imugene Limited Announces Phase 1 onCARlytics Solid Tumour Trial Advances to Combination Arm Treatment	11.03.
Imugene's Phase 1 onCARlytics Trial to Commence Combination Arm Treatment	11.03.
Imugene Widens Per-Share Loss in H1 FY24 to AU$0.01 on Higher General, R&D Spending	29.02.
Imugene Reports H1 FY24 Loss Widens as Expenses Grow	28.02.
Imugene Limited Reports Earnings Results for the Half Year Ended December 31, 2023	28.02.
Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts	22.02.
Imugene doses first patient in intravenous monotherapy arm of Phase 1 clinical trial	15.02.
Imugene’s Phase 1 onCARlytics Trial Doses First Patient in Intravenous Monotherapy Arm	15.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Imugene Limited

Aktien

891460

AU000000IMU9

IMU

Andere Sprachen

Filter